ライフサイエンスコーパス: malignant neoplasm

1 e MMP but not preferentially in those with a malignant neoplasm.

2 and contributes to STAT3 activation in this malignant neoplasm.

3 for the diagnosis and staging of this highly malignant neoplasm.

4 te cause of death could be attributed to the malignant neoplasm.

5 Seventy-two patients have developed a second malignant neoplasm.

6 udy who were ultimately diagnosed with a CNS malignant neoplasm.

7 No patient developed tuberculosis or a malignant neoplasm.

8 ounger than 18 years or who had an abdominal malignant neoplasm.

9 : SOTRs and patients with HIV or hematologic malignant neoplasm.

10 ive RPF or malignant RPF and retroperitoneal malignant neoplasm.

11 the defense against recurring pathogens and malignant neoplasms.

12 ive prognostic factor for a diverse range of malignant neoplasms.

13 tion by PET in patients with newly diagnosed malignant neoplasms.

14 ponses towards other infectious diseases and malignant neoplasms.

15 s and seems to be associated with concurrent malignant neoplasms.

16 at this phosphorylation event might identify malignant neoplasms.

17 s diseases, such as autoimmune disorders and malignant neoplasms.

18 icity, hearing loss, infertility, and second malignant neoplasms.

19 Two had second malignant neoplasms.

20 ep in the in the proliferation and spread of malignant neoplasms.

21 protein family that is expressed in several malignant neoplasms.

22 in a variety of disease processes, including malignant neoplasms.

23 creased susceptibility to the development of malignant neoplasms.

24 hway and is inactivated in a wide variety of malignant neoplasms.

25 ed cardiac function, infertility, and second malignant neoplasms.

26 ents with a variety of primary and secondary malignant neoplasms.

27 hyperplasia, and a predisposition to develop malignant neoplasms.

28 eptor staining in the majority (15 of 19) of malignant neoplasms.

29 sociated neovasculature of a wide variety of malignant neoplasms.

30 Resected livers were evaluated for malignant neoplasms.

31 romising new strategies for the treatment of malignant neoplasms.

32 dgkin's disease is the development of second malignant neoplasms.

33 IGF-1 also facilitate growth of a number of malignant neoplasms.

34 genome-wide association studies of lymphoid malignant neoplasms.

35 phase 3 trials for adults with hematological malignant neoplasms.

36 2 of 12, 17%) were the most common nonneural malignant neoplasms.

37 dardized incidence ratio (SIR) of subsequent malignant neoplasms.

38 tropenia, cardiotoxic effects, and secondary malignant neoplasms.

39 -FDG) PET/MRI diagnostic performance in lung malignant neoplasms.

40 nearly all of the mortality associated with malignant neoplasms.

41 4%]), and oral cavity (85 334 patients [1%]) malignant neoplasms.

42 nconsistent with mortality trends across all malignant neoplasms.

43 e or later therapy for several hematological malignant neoplasms.

44 carcinomas (BCCs), are the most common human malignant neoplasms.

45 , 77 (13.5%) benign neoplasms, and 18 (3.2%) malignant neoplasms.

46 bromas, renal tumours and uterine benign and malignant neoplasms.

47 ere diagnosed in 54 individuals as benign or malignant neoplasms.

48 ion approvals for patients with a variety of malignant neoplasms.

49 g delivery applications for the treatment of malignant neoplasms.

50 n increased risk of posttransplant cutaneous malignant neoplasms.

51 ell depletion are risk factors for cutaneous malignant neoplasms.

52 reased risk for treatment-related subsequent malignant neoplasms.

53 known to distinguish borderline from overtly malignant neoplasms.

54 thrombocytopenic patients with hematological malignant neoplasms?

55 erebrovascular disease 0.88 [0.81-0.95], all malignant neoplasms 0.92 [0.88-0.95], and respiratory di

56 , unintentional injury (1.015, 1.011-1.018), malignant neoplasm (1.014, 1.013-1.016), diabetes (1.013

57 l burden in people aged 60 years and older), malignant neoplasms (15.1%), chronic respiratory disease

58 rt (268.5), cerebrovascular disease (242.3), malignant neoplasms (214.1), pneumonia and influenza (45

59 : overall 95.5; death due to HL 38.3, second malignant neoplasms 23.9, and cardiovascular disease 13.

60 Cardiovascular diseases (34.7%) and malignant neoplasms (31.8%) were the leading causes of d

61 n-communicable causes 40.9%; injuries 15.1%; malignant neoplasms 5.1%; neuropsychiatric conditions 10

62 ssue in assessing the risk of second-primary malignant neoplasms, a major late effect of concern, usi

63 y tumors, metastatic disease, or hematologic malignant neoplasms admitted to medical and surgical int

64 05 of 129 patients who developed a secondary malignant neoplasm after ALL treatment on 7 consecutive

65 ay a major role in the etiology of secondary malignant neoplasm after treatment for childhood ALL, ac

66 t an increased risk of developing subsequent malignant neoplasms among those who have survived childh

67 harts of 149 patients with an extrapulmonary malignant neoplasm and a solitary pulmonary nodule.

68 range of late complications, with subsequent malignant neoplasm and cardiovascular disease representi

69 m peritoneal carcinomatosis from any primary malignant neoplasm and excluded case studies, curative s

70 ents with a historical diagnosis of invasive malignant neoplasm and laboratory-confirmed SARS-CoV-2 i

71 ry hypothyroidism, breast cancer as a second malignant neoplasm and suggests an increased prevalence

72 ic fluid was shown in 21 of 25 patients with malignant neoplasms and 48 of 62 patients with benign di

73 igases are often highly accumulated in human malignant neoplasms and are believed to possess oncogeni

74 nts can increase the risk of primary myeloid malignant neoplasms and are more frequent among patients

75 le in a fraction of patients across multiple malignant neoplasms and can be reactivated by targeting

76 Secondary malignant neoplasms and cardiovascular disease represent

77 h-related causes, including other subsequent malignant neoplasms and cardiovascular or pulmonary dise

78 d in the neovasculature of a wide variety of malignant neoplasms and may be an effective target for m

79 ion between insulin-like growth factor-I and malignant neoplasms and quality-of-life issues with long

80 with a small (T1) lung lesion suspicious for malignant neoplasms and with radiographic features sugge

81 rally longer latency periods (heart disease, malignant neoplasm, and cerebrovascular disease).

82 ression in four (10%) patients and dyspnoea, malignant neoplasm, and sepsis in one (2%) patient each)

83 ms or signs of VLS, scarring, development of malignant neoplasms, and adverse effects.

84 ts of treatment, such as infertility, second malignant neoplasms, and cardiopulmonary injury.

85 t conditions, medically confirmed subsequent malignant neoplasms, and cause of death based on the Nat

86 data for the subset who developed cutaneous malignant neoplasms, and cutaneous malignant neoplasm ri

87 owth controller, is highly activated in some malignant neoplasms, and its clinical implications are u

88 lts, 10 (6.8%) benign neoplasms, five (3.4%) malignant neoplasms, and two (1.4%) isolated p53 signatu

89 atients had benign cysts; eight, borderline (malignant) neoplasms; and three, carcinoma in situ lesio

90 i-laminin 332 reactivity was associated with malignant neoplasm (aOR, 23.27; 95% CI, 1.83-296.68), wh

91 Second malignant neoplasms are a major cause of late morbidity

92 Second malignant neoplasms are a serious complication after suc

93 Malignant neoplasms are consistently among the top four

94 Clinical trials for metastatic malignant neoplasms are increasingly being extended to p

95 ect Black persons with various hematological malignant neoplasms are substantial, yet little is known

96 Cutaneous malignant neoplasms are the most common subsequent neopl

97 inogenesis in this model, we report that all malignant neoplasms arise from the proximal region of th

98 us cell carcinoma (HNSCC) is the most common malignant neoplasm arising in the mucosa of the upper ae

99 ion, and exhibited progression to aggressive malignant neoplasms, as is often observed in human carci

100 (CTCL) is a group of rare, complex cutaneous malignant neoplasms associated with significant disease

101 with known race and ethnicity and no non-PC malignant neoplasm before study entry receiving care thr

102 with a high incidence of medulloblastoma, a malignant neoplasm believed to arise from immature precu

103 patients age 20 to 40 years diagnosed with a malignant neoplasm between 2007 and 2009.

104 es, predominant viral variant, treatment for malignant neoplasm, booster vaccination, and antiviral t

105 pecially in SOTRs and those with hematologic malignant neoplasm, but not patients with HIV.

106 Autopsy often reveals new diagnoses of malignant neoplasms, but as technological advances to im

107 late-occurring complications such as second malignant neoplasms, cardiovascular disease, endocrinopa

108 enefit nor harm in terms of the incidence of malignant neoplasms, cardiovascular disease, or death fr

109 determinant in 3 (ie, diseases of the heart, malignant neoplasms, cerebrovascular diseases) of the to

110 on in hyperplastic tissues and in benign and malignant neoplasms compared with normal tissues.

111 ions in IS patients (SOTRs, HIV, hematologic malignant neoplasm) compared with IC patients.

112 ith the neovasculature of a wide spectrum of malignant neoplasms: conventional (clear cell) renal car

113 ted with an increased severity of subsequent malignant neoplasms (CTCAE grade >=4 vs grade <4: odds r

114 otype, AO exposure information, and lymphoid malignant neoplasm diagnosis from January 1, 1965, throu

115 erson-years; the highest AERs were found for malignant neoplasms, diseases of digestive organs, and d

116 ors of childhood cancer may develop a second malignant neoplasm during adulthood and therefore requir

117 % CI, 1.53-2.49; P < .001), and not having a malignant neoplasm (eg, BRCA carriers) (OR, 3.13; 95% CI

118 Malignant neoplasms enhanced (median, 38.1 HU; range, 14

119 When analyzed by type of malignant neoplasm, ERCP was associated with a lower rat

120 Malignant neoplasms evolve in response to changes in onc

121 In the beta carotene group, 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as

122 Malignant neoplasms exhibit an elevated rate of glycolys

123 current standard care is ablative surgery of malignant neoplasm, followed by tongue reconstruction wi

124 The standardized incidence ratio for all malignant neoplasms for all participants was 72% (95% CI

125 D] age at diagnosis, 78.4 [10.5] years) with malignant neoplasms found in the face, scalp, neck, ear,

126 8.8% (95% CI, 79.8%-94.1%) in distinguishing malignant neoplasms from benign and NIFTP tumors.

127 ients with malignant RPF and retroperitoneal malignant neoplasm; group II, 16 patients with chronic R

128 with metastatic solid tumors and hematologic malignant neoplasms had worse outcomes (eg, mortality OR

129 activators for targeted molecular therapy of malignant neoplasms harboring WT p53 and elevated levels

130 The high frequency of Ras mutations in human malignant neoplasms has led to Ras being a desirable che

131 , and ethnicity), comorbidities (hematologic malignant neoplasms, heart disease, diabetes, HIV infect

132 Subsequent malignant neoplasm history was determined in 13,136 part

133 dults (aged 67-90 years) without hematologic malignant neoplasms (HMs) who were participants in the A

134 HR, 1.7; 95% CI, 1.2-2.5), non-breast second malignant neoplasm (HR, 2.6; 95% CI 1.4-5.1), or a serio

135 ide attempts (HR 3.14, 95% CI 3.00-3.28) and malignant neoplasms (HR 2.09, 95% CI 2.02-2.16).

136 , 95% confidence interval (CI): 1.03, 1.07), malignant neoplasms (HR = 1.06, 95% CI: 1.03, 1.09), lun

137 Diagnosis of malignant neoplasm, identified and classified according

138 adiotherapy, and 42 (59%) developed a second malignant neoplasm in a previous radiotherapy field.

139 rcinoma (BCC) of the skin is the most common malignant neoplasm in humans.

140 ma (33.3%; aOR, 2.08; 95% CI, 1.18-3.66) and malignant neoplasm in the small intestine (28.6%; aOR, 2

141 benign nodal hyperplasia in 251 patients and malignant neoplasm in two patients.

142 One hundred eleven malignant neoplasms in 100 patients had been either undi

143 vents included infections in 10 patients and malignant neoplasms in 3 patients.

144 er (HCC) are the most common primary hepatic malignant neoplasms in childhood.

145 ars of YPLL than did either heart disease or malignant neoplasms in every year of observation.

146 Given the increased risk of cutaneous malignant neoplasms in hematopoietic cell transplant rec

147 lication and smoking, and the development of malignant neoplasms in kidney transplant recipients.

148 We interrogated RNA-Seq data from 3,775 malignant neoplasms in The Cancer Genome Atlas database

149 study included all patients with hematologic malignant neoplasms in the national Veterans Health Admi

150 s who underwent REn for benign and low-grade malignant neoplasms in the pancreatic head and uncinate

151 ce between clinical and autopsy diagnoses of malignant neoplasms in this study is 44%, which is simil

152 g the group of female patients, there were 5 malignant neoplasms in which the COVID-19 in-hospital ca

153 ivors, risk factors for subsequent cutaneous malignant neoplasms included age of 50 years and older a

154 Malignant neoplasms, including colon cancers, are though

155 ydroxylase (AAH) is overexpressed in various malignant neoplasms, including hepatocellular carcinomas

156 e at increased risk of CUP and several other malignant neoplasms, including lung, pancreatic, and col

157 basal cell carcinoma, and multiple internal malignant neoplasms, including mesothelioma and renal ce

158 ew therapies to treat patients with advanced malignant neoplasms, including metastatic non-small cell

159 capivasertib was demonstrated in refractory malignant neoplasms, including rare cancers.

160 immunodeficiency virus (HIV) or hematologic malignant neoplasms, increases the risk of developing no

161 2q24 are frequently reported in a variety of malignant neoplasms, indicating the presence of a tumor

162 y-related health care utilization, including malignant neoplasm, inflammatory bowel disease, human im

163 The transformation of a healthy cell into a malignant neoplasm involves numerous genetic mutations a

164 mas represent a diverse group of hematologic malignant neoplasms involving different tissues within t

165 hyroid nodules are benign, the potential for malignant neoplasms is associated with unnecessary worku

166 te between clinical and autopsy diagnoses of malignant neoplasms is large and confirms the importance

167 s, but how these benign lesions develop into malignant neoplasms is not understood.

168 the increase in incidence of more aggressive malignant neoplasms is significantly higher than expecte

169 incidence of IOS was calculated with second malignant neoplasm, late recurrence, and death as compet

170 ected (PMR=1.21, 95% CI 1.14-1.28) to have a malignant neoplasm listed on their death certificates, b

171 esota to determine the incidence of post-BMT malignant neoplasms (MNs).

172 The five leading causes of death were malignant neoplasms (mortality, 374.1 per 100,000 person

173 ed elevated when patients with pretransplant malignant neoplasms (n = 1124) were excluded (SMR, 1.93

174 and parasitic diseases (n = 62 [11.8%]), and malignant neoplasms (n = 20 [3.8%]).

175 ry nodules were studied in 107 patients with malignant neoplasms (n = 52), granulomas (n = 51), and b

176 Second malignant neoplasms occurred mainly in patients treated

177 Breast carcinoma (BC) is the most common malignant neoplasm occurring in women, posing a serious

178 y neoplasm (odds ratio, 2.58; P < .0001) and malignant neoplasm (odds ratio, 4.94; P = .005).

179 as also an independent prognostic factor for malignant neoplasms (odds ratio, 12.76; 95% CI, 2.43-66.

180 ma is the second most common solid pediatric malignant neoplasm of bone and soft tissue.

181 duct carcinoma (CDC) of the kidney is a rare malignant neoplasm of distal nephron origin.

182 m and sense organs (2.50, 1.40 to 4.44), and malignant neoplasm of gynecological organs (2.76, 1.79 t

183 Melanoma is a highly malignant neoplasm of melanocytes with considerable meta

184 atic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origi

185 Rhabdomyosarcoma is a malignant neoplasm of primitive mesenchyme exhibiting sk

186 Neuroblastoma (NB) is a pediatric malignant neoplasm of sympathoadrenal origin.

187 Cholangiocarcinoma is a highly malignant neoplasm of the biliary tree.

188 Cervical cancer, the malignant neoplasm of the cervix uteri is the second mos

189 clear cell renal carcinoma, the most common malignant neoplasm of the human kidney.

190 iary cystadenocarcinoma is a rare epithelial malignant neoplasm of the liver or extrahepatic bile duc

191 rt, we present a case of an undifferentiated malignant neoplasm of unknown origin presenting as benig

192 angioendothelioma (EH) is a rare, low-grade, malignant neoplasm of vascular origin that may develop a

193 and IL-23 participate in the development of malignant neoplasms of keratinocytes.

194 , collected data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 20 y

195 Malignant neoplasms of the hepatopancreaticobiliary (HPB

196 Malignant neoplasms of the ocular surface are uncommon b

197 Pancreatoblastomas are unusual malignant neoplasms of the pediatric pancreas that may a

198 The most common human cancers are malignant neoplasms of the skin.

199 excess subsequent all-cause, cancer (second malignant neoplasms only), and cardiac mortality rates.

200 ry at age 60 years or older without previous malignant neoplasm or cardiovascular disease between 198

201 None of the patients demonstrated second malignant neoplasm or systemic metastasis.

202 elines for survivors at high risk for second malignant neoplasms or cardiac dysfunction and to the Am

203 late differences in the overall incidence of malignant neoplasms or cardiovascular disease, or in ove

204 id tumors, whereas patients with hematologic malignant neoplasms or less severe illness seem to benef

205 There were no malignant neoplasms or opportunistic infections reported

206 n (OR, 1.02; 95% CI, 1.01-1.03), concomitant malignant neoplasm (OR, 2.18; 95% CI, 1.47-3.24), and pa

207 esence of any progressive chronic condition, malignant neoplasm, or significant chronic conditions in

208 r esophageal/laryngeal involvement; internal malignant neoplasm; or BP180 ELISA score.

209 Cholangiocarcinoma is a malignant neoplasm originating from cholangiocytes.

210 By contrast, malignant neoplasms other than leukaemia were listed on

211 a significantly increased risk of subsequent malignant neoplasms, particularly bone and soft tissue s

212 ants were similarly distributed in secondary malignant neoplasm patients and the overall ALL patient

213 eases, the age-adjusted mortality due to all malignant neoplasms plateaued, then decreased by 1.0 per

214 f the same cancer occurring as first primary malignant neoplasm (PM) by age.

215 Angiosarcoma is an aggressive vascular malignant neoplasm presenting either as a primary or sec

216 d in age at diagnosis, sex, history of other malignant neoplasm, presenting visual acuity, distance o

217 rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, w

218 tinal obstruction (10 [5%] of 204 patients), malignant neoplasm progression (10 [5%]), and anaemia (n

219 ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), inc

220 The most common serious adverse events were malignant neoplasm progression (eight of 52 [15%] with p

221 two patients treated with standard of care (malignant neoplasm progression and pneumonia).

222 pecified cause, large intestine perforation, malignant neoplasm progression, and Stevens-Johnson synd

223 se event of any grade or grade 3 or more was malignant neoplasm progression.

224 Contralateral lobe malignant neoplasm recurrence was 2.3% in the HT group,

225 263 (2.1%) subsequent malignant neoplasm-related deaths (44 [1.0%] in the SJLI

226 ociated with an increased risk of subsequent malignant neoplasm-related mortality (SJLIFE: subdistrib

227 Cumulative subsequent malignant neoplasm-related mortality at 10 years after t

228 a group of histologically diverse benign and malignant neoplasms, represent a challenging problem for

229 iferation, which is a hallmark of aggressive malignant neoplasms, requires a general increase in prot

230 guidelines, proportions of any neoplasm and malignant neoplasm, respectively, were 1% and 0% in SRU

231 s an option, proportions of any neoplasm and malignant neoplasm, respectively, were 1% and 0% in SRU

232 Assessing malignant neoplasm risk among patients with long-term bi

233 cutaneous malignant neoplasms, and cutaneous malignant neoplasm risk factors were extracted from incl

234 In the assessment of second-primary malignant neoplasm risk, attained age is a critical fact

235 posure is associated with increased lymphoid malignant neoplasm risk, the details of this association

236 diseases (RR, 1.69; 95% CI, 1.61-1.77), and malignant neoplasms (RR, 1.63; 95% CI, 1.59-1.68).

237 Otherwise, borderline-malignant neoplasms seemed to have a similar spectrum of

238 emale survivors at average risk for a second malignant neoplasm show reasonable rates of screening fo

239 relationships between colorectal subsequent malignant neoplasm (SMN) incidence and colorectum-specif

240 tic exposures are associated with subsequent malignant neoplasm (SMN) risk.

241 exist on chemotherapy-associated subsequent malignant neoplasm (SMN) risk.

242 oma (CRC) has been described as a subsequent malignant neoplasm (SMN), although little is known about

243 cer (GCC) are at increased risk for a second malignant neoplasm (SMN).

244 SC) had a cumulative incidence of subsequent malignant neoplasm (SMN; ie, malignancies excluding NMSC

245 Second malignant neoplasms (SMN) are devastating late complicat

246 Secondary malignant neoplasms (SMN) are increasingly common compli

247 Second malignant neoplasms (SMN) are therapy-induced malignanci

248 Second malignant neoplasms (SMNs) after diagnosis of childhood

249 We assessed mortality and second malignant neoplasms (SMNs) among 1082 5-year survivors o

250 cts of cancer and its treatment, with second malignant neoplasms (SMNs) comprising one of the most po

251 Despite recognition that second malignant neoplasms (SMNs) contribute significantly to m

252 azoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's di

253 dose and fractionation on risk of subsequent malignant neoplasms (SMNs) in the era of reduced-intensi

254 s (CCS) are at risk of developing subsequent malignant neoplasms (SMNs) resulting from exposure to pr

255 Second malignant neoplasms (SMNs) were ascertained by medical r

256 and standardized incidence ratios for second malignant neoplasms (SMNs) were calculated.

257 s (SIRs), excess absolute risk of subsequent malignant neoplasms (SMNs), and relative risks (RRs) for

258 late effects of cancer therapy), subsequent malignant neoplasms (SMNs), chronic health conditions, a

259 at risk for radiation therapy-induced second malignant neoplasms (SMNs).

260 dgkin's lymphoma (HL) are at risk for second malignant neoplasms (SMNs).

261 L)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs).

262 (CCSs) are at increased risk for subsequent malignant neoplasms (SMNs).

263 survivors have increased risk of subsequent malignant neoplasms (SMNs).

264 inal disease, late effects (including second malignant neoplasms [SMNs], cardiac causes, pulmonary di

265 gh the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect a

266 Six (1%) survivors developed a subsequent malignant neoplasm (standardised incidence ratio 2.6, 95

267 y has resulted in improved outcomes in other malignant neoplasms, such as non-small cell lung cancer,

268 arcinoma (MCC) is a cutaneous neuroendocrine malignant neoplasm that can be highly aggressive and ult

269 oma (OSCC) accounts for more than 90% of the malignant neoplasms that arise in the mucosa of the uppe

270 Ampullary carcinomas are highly malignant neoplasms that can have either intestinal or p

271 ociated with myelogenous leukemias and other malignant neoplasms, this study concludes that K12 is a

272 n clinical trials for treatment of different malignant neoplasms; trametinib dimethyl sulfoxide was a

273 d patients with biliary obstruction due to a malignant neoplasm treated with a single-type, commercia

274 Thirty-one patients with known or suspected malignant neoplasms underwent imaging with both methods,

275 ; P < .001), and the presence of hematologic malignant neoplasm was associated with 1.74 times the od

276 required follow-up and in whom a new primary malignant neoplasm was detected.

277 s aspiration biopsy samples acquired because malignant neoplasm was suspected clinically that were ob

278 nd smoking, the incidence rate ratio for all malignant neoplasms was 0.89 (95% CI: 0.80, 1.00).

279 median serum CA19-9 level for patients with malignant neoplasms was 210 vs 15 U/mL for those without

280 Risk of second malignant neoplasms was highest among patients treated w

281 Diagnostic accuracy for malignant neoplasms was highest at an MPD diameter cutof

282 A history of noncutaneous malignant neoplasms was observed in 21.3% of the patient

283 The annual YPLL attributed to malignant neoplasms was similar to that for heart diseas

284 tcomes (nonneoplastic cyst, benign neoplasm, malignant neoplasm) was compared in each rating group by

285 erapy has been used in the treatment of some malignant neoplasms, we evaluated attenuated Salmonella

286 cy of core-needle biopsy in the detection of malignant neoplasms were 61% (11 of 18), 100% (181 of 18

287 Observed-to-expected (O/E) ratios for second malignant neoplasms were calculated with the use of age-

288 A total of 1,466 incident malignant neoplasms were diagnosed during the study peri

289 Malignant neoplasms were enhanced (median, 46.5 HU; rang

290 Second malignant neoplasms were evaluated among 32,251 women wi

291 The most common malignant neoplasms were nonmelanoma skin (n = 35), brea

292 No second malignant neoplasms were observed.

293 tients with diagnostic codes for hematologic malignant neoplasms who had documented vaccination follo

294 fear their cancer will recur or a subsequent malignant neoplasm will develop.

295 Pancreatic cancer is a malignant neoplasm with a high mortality rate.

296 id dendritic cell neoplasm (BPDCN) is a rare malignant neoplasm with cutaneous manifestations and a r

297 Anorectal melanoma is a rare malignant neoplasm with variable natural history and non

298 (ESFT) comprises several well-characterized malignant neoplasms with particularly aggressive behavio

299 adenocarcinoma is one of the most aggressive malignant neoplasms with poor outcomes.

300 to differential diagnosis of chronic RPF and malignant neoplasms with RPF morphology.